SG10201912270PA - Condensed heterocyclic compound - Google Patents

Condensed heterocyclic compound

Info

Publication number
SG10201912270PA
SG10201912270PA SG10201912270PA SG10201912270PA SG10201912270PA SG 10201912270P A SG10201912270P A SG 10201912270PA SG 10201912270P A SG10201912270P A SG 10201912270PA SG 10201912270P A SG10201912270P A SG 10201912270PA SG 10201912270P A SG10201912270P A SG 10201912270PA
Authority
SG
Singapore
Prior art keywords
heterocyclic compound
condensed heterocyclic
condensed
compound
heterocyclic
Prior art date
Application number
SG10201912270PA
Inventor
Youichi Kawakita
Takuto Kojima
Noriyuki Nii
Yoshiteru Ito
Nobuki Sakauchi
Hiroshi Banno
Xin Liu
Koji Ono
Keisuke Imamura
Shinichi Imamura
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of SG10201912270PA publication Critical patent/SG10201912270PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG10201912270PA 2016-04-28 2017-04-27 Condensed heterocyclic compound SG10201912270PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016091717 2016-04-28

Publications (1)

Publication Number Publication Date
SG10201912270PA true SG10201912270PA (en) 2020-02-27

Family

ID=60159711

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201809243YA SG11201809243YA (en) 2016-04-28 2017-04-27 Condensed heterocyclic compound
SG10201912270PA SG10201912270PA (en) 2016-04-28 2017-04-27 Condensed heterocyclic compound

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201809243YA SG11201809243YA (en) 2016-04-28 2017-04-27 Condensed heterocyclic compound

Country Status (19)

Country Link
US (3) US10577382B2 (en)
EP (1) EP3450436B1 (en)
JP (2) JP6924182B2 (en)
KR (1) KR102431405B1 (en)
CN (1) CN109415384B (en)
BR (1) BR112018072039B1 (en)
CA (1) CA3021185C (en)
DK (1) DK3450436T3 (en)
EA (1) EA039529B1 (en)
ES (1) ES2927529T3 (en)
HR (1) HRP20221277T1 (en)
HU (1) HUE059954T2 (en)
LT (1) LT3450436T (en)
MA (1) MA44781B1 (en)
PL (1) PL3450436T3 (en)
PT (1) PT3450436T (en)
RS (1) RS63656B1 (en)
SG (2) SG11201809243YA (en)
WO (1) WO2017188374A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3450436T3 (en) * 2016-04-28 2022-09-12 Takeda Pharmaceuticals Co CONDENSED HETEROCYCLIC COMPOUND
CN113773247A (en) * 2021-07-23 2021-12-10 无锡海伦生物科技有限公司 Preparation method of 2-amino-5-iodopyridine
WO2023190967A1 (en) * 2022-03-31 2023-10-05 Chordia Therapeutics株式会社 Biomarker for treatment of solid cancer by imidazo[4,5-b]pyridine derivative
CN115006411A (en) * 2022-07-26 2022-09-06 中南大学湘雅医院 Application of eudragit compounds, medicine and preparation method thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01011832A (en) 1999-05-21 2002-06-21 Squibb Bristol Myers Co Pyrrolotriazine inhibitors of kinases.
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
JP5630867B2 (en) * 2008-08-05 2014-11-26 第一三共株式会社 Imidazopyridin-2-one derivatives
CN102595899A (en) * 2009-08-10 2012-07-18 埃皮瑟瑞克斯有限公司 Indazoles as WNT/B-catenin signaling pathway inhibitors and therapeutic uses thereof
ES2556350T3 (en) * 2009-08-10 2016-01-15 Samumed, Llc Indazole inhibitors of the Wnt signaling pathway and its therapeutic uses
WO2012003576A1 (en) 2010-07-06 2012-01-12 Université de Montréal Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
DK3450436T3 (en) * 2016-04-28 2022-09-12 Takeda Pharmaceuticals Co CONDENSED HETEROCYCLIC COMPOUND

Also Published As

Publication number Publication date
PT3450436T (en) 2022-09-29
EP3450436A4 (en) 2019-10-30
EP3450436A1 (en) 2019-03-06
HUE059954T2 (en) 2023-01-28
WO2017188374A1 (en) 2017-11-02
SG11201809243YA (en) 2018-11-29
US10577382B2 (en) 2020-03-03
RS63656B1 (en) 2022-11-30
CA3021185A1 (en) 2017-11-02
CN109415384A (en) 2019-03-01
HRP20221277T1 (en) 2022-12-23
MA44781A (en) 2019-03-06
EP3450436B1 (en) 2022-07-27
LT3450436T (en) 2022-09-12
BR112018072039B1 (en) 2023-12-26
BR112018072039A2 (en) 2019-02-12
CN109415384B (en) 2022-01-11
JP7130098B2 (en) 2022-09-02
KR20190002547A (en) 2019-01-08
JP6924182B2 (en) 2021-08-25
EA201892449A1 (en) 2019-05-31
ES2927529T3 (en) 2022-11-08
EA039529B1 (en) 2022-02-07
CA3021185C (en) 2024-06-04
PL3450436T3 (en) 2022-12-27
US20190106437A1 (en) 2019-04-11
JPWO2017188374A1 (en) 2019-02-28
DK3450436T3 (en) 2022-09-12
MA44781B1 (en) 2022-10-31
KR102431405B1 (en) 2022-08-10
US20200140462A1 (en) 2020-05-07
US20210115067A1 (en) 2021-04-22
JP2021176901A (en) 2021-11-11
US10981934B2 (en) 2021-04-20
US11390634B2 (en) 2022-07-19

Similar Documents

Publication Publication Date Title
ZA201807249B (en) Heterocyclic compound
IL253937A0 (en) Condensed heterocyclic compounds and pesticides
IL247018A0 (en) Heterocyclic compound
IL285105A (en) Heterocyclic compound
EP3372604A4 (en) Condensed heterocyclic compound
EP3239142A4 (en) Condensed heterocyclic compound
PT3643718T (en) Heterocyclic compound
IL258791A (en) Condensed heterocyclic compound
EP3660003C0 (en) Heterocyclic compound
SG10201912270PA (en) Condensed heterocyclic compound
GB201617103D0 (en) Compound
EP3693368C0 (en) Heterocyclic compound
EP3693360C0 (en) Heterocyclic compounds
HK1249105A1 (en) Nitrogen-containing heterocyclic compound
SI3159335T1 (en) Novel heterocyclic compound
IL254890A0 (en) Heterocyclic compound
GB201612652D0 (en) Novel compound
ZA201907792B (en) Heterocyclic compound
GB201610497D0 (en) Compound
EP3178810A4 (en) Condensed heterocyclic compound
IL266099A (en) Heterocyclic compound
ZA201907793B (en) Heterocyclic compound
GB201619531D0 (en) Compound
GB201619526D0 (en) Compound
GB201613035D0 (en) Compound